Trillium Closes US$30 Million Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares
TORONTO, ONTARIO--(Marketwired - Jun 1, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the closing of its previously …